• Theriva Biologics highlighted peer-reviewed Nature Medicine publication of results from the VIRAGE Phase 2b trial of VCN-01 in metastatic pancreatic cancer.
• Results were already presented via the publication, showing improved survival-related outcomes when VCN-01 was added to standard chemotherapy versus chemotherapy alone.
• Analyses supported an immune-mediated effect alongside tumor-stroma disruption, expanding potential combination-use positioning across pancreatic cancer regimens.
• VIRAGE2 Phase 2a is under way to test more frequent repeat dosing to support a future Phase 3 regimen decision.
• Initial pharmacodynamic and safety-tolerability data are expected in Q3 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Theriva Biologics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609300800PRIMZONEFULLFEED9836234) on September 30, 2026, and is solely responsible for the information contained therein.